ATR inhibition reverses the resistance of homologous recombination deficient MGMT low /MMR proficient cancer cells to temozolomide.

Autor: El Touny LH; Molecular Pharmacology Laboratory, Leidos Biomedical Research Inc., FNLCR, Frederick, MD, USA.; Current address: Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, NIH, Bethesda, MD, USA., Hose C; Molecular Pharmacology Laboratory, Leidos Biomedical Research Inc., FNLCR, Frederick, MD, USA., Connelly J; Molecular Pharmacology Laboratory, Leidos Biomedical Research Inc., FNLCR, Frederick, MD, USA., Harris E; Molecular Pharmacology Laboratory, Leidos Biomedical Research Inc., FNLCR, Frederick, MD, USA., Monks A; Molecular Pharmacology Laboratory, Leidos Biomedical Research Inc., FNLCR, Frederick, MD, USA., Dull AB; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Leidos Biomedical Research Inc., FNLCR, Frederick, MD, USA., Wilsker DF; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Leidos Biomedical Research Inc., FNLCR, Frederick, MD, USA., Hollingshead MG; Biological Testing Branch, NCI, Frederick, MD, USA., Gottholm-Ahalt M; Biological Testing Branch, NCI, Frederick, MD, USA., Alcoser SY; Biological Testing Branch, NCI, Frederick, MD, USA., Mullendore ME; In Vivo Evaluation Program, Leidos Biomedical Research Inc., FNLCR, Frederick, MD, USA., Parchment RE; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Leidos Biomedical Research Inc., FNLCR, Frederick, MD, USA., Doroshow JH; Division of Cancer Treatment and Diagnosis, NCI, Bethesda, MD, USA.; Developmental Therapeutics Branch, Center for Cancer Research, NCI, National Institutes of Health, Bethesda, MD, USA., Teicher BA; Developmental Therapeutics Branch, Center for Cancer Research, NCI, National Institutes of Health, Bethesda, MD, USA.; Molecular Pharmacology Branch, Developmental Therapeutics Program, NCI, Rockville, MD, USA., Rapisarda A; Molecular Pharmacology Laboratory, Leidos Biomedical Research Inc., FNLCR, Frederick, MD, USA.
Jazyk: angličtina
Zdroj: Oncotarget [Oncotarget] 2021 Oct 12; Vol. 12 (21), pp. 2114-2130. Date of Electronic Publication: 2021 Oct 12 (Print Publication: 2021).
DOI: 10.18632/oncotarget.28090
Abstrakt: The therapeutic efficacy of temozolomide (TMZ) is hindered by inherent and acquired resistance. Biomarkers such as MGMT expression and MMR proficiency are used as predictors of response. However, not all MGMT low/-ve /MMR proficient patients benefit from TMZ treatment, indicating a need for additional patient selection criteria. We explored the role of ATR in mediating TMZ resistance and whether ATR inhibitors (ATRi) could reverse this resistance in multiple cancer lines. We observed that only 31% of MGMT low/-ve /MMR proficient patient-derived and established cancer lines are sensitive to TMZ at clinically relevant concentrations. TMZ treatment resulted in DNA damage signaling in both sensitive and resistant lines, but prolonged G 2 /M arrest and cell death were exclusive to sensitive models. Inhibition of ATR but not ATM, sensitized the majority of resistant models to TMZ and resulted in measurable DNA damage and persistent growth inhibition. Also, compromised homologous recombination (HR) via RAD51 or BRCA1 loss only conferred sensitivity to TMZ when combined with an ATRi. Furthermore, low REV3L mRNA expression correlated with sensitivity to the TMZ and ATRi combination in vitro and in vivo . This suggests that HR defects and low REV3L levels could be useful selection criteria for enhanced clinical efficacy of an ATRi plus TMZ combination.
Competing Interests: CONFLICTS OF INTEREST Authors have no conflicts of interest to declare.
(Copyright: © 2021 El Touny et al.)
Databáze: MEDLINE
Externí odkaz: